About this Research Topic
Immunotherapy has emerged as a transformative approach in cancer treatment, harnessing the patient's immune system to combat malignancies. The diversity of patient responses to therapies such as immune checkpoint inhibitors highlights the necessity for precise biomarkers that can accurately predict and monitor therapeutic outcomes. Current research emphasizes the complexity of interactions within the tumor microenvironment, revealing that the effectiveness of biomarkers like PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) varies across different cancers and patient demographics. There is a critical demand for expanded research into less explored areas such as the tumor microenvironment and biomarkers derived from liquid biopsies to deepen our comprehension of the immune landscape within cancer contexts. This necessity is particularly urgent for gynecological cancers which have benefitted from immunotherapy but suffer from limited research focus.
This research aims to overcome existing challenges and seize the opportunity to advance the identification and validation of immune biomarkers capable of prognosticating and predicting responses to immunotherapies, especially beyond the well-recognized markers like PD-L1, TMB, and MSI. Recent innovations integrating high-dimensional data analysis and multi-omics have propelled forward our understanding of the immunological landscape. However, these methodologies require further refinement and clinical integration to enhance precision in immunotherapy strategies. This research encourages contributions that span basic research, translational applications, and clinical investigations, particularly studies utilizing paired tumor samples, liquid biopsies, and exploring the microbiome’s role in modulating immune responses.
To deal with the immune dynamics of cancer, this research topic calls for contributions encapsulating a range from basic research findings to advanced translational insights. Specific themes of interest include, but are not limited to:
o Novel immune predictive and prognostic biomarkers in oncology.
o Mechanisms of immune evasion and strategies to counteract resistance to immunotherapy.
o Research utilizing paired tumor samples or biomarkers from liquid biopsies to understand tumor-immune interplay.
o Examination of immune cell interactions within tumor environments in relation to immunotherapeutic efficacy.
o The influence of microbiome and metabolome analyses on immune responses and clinical outcomes.
o Application of multi-omics to investigate immune biomarkers in oncology.
o Focused studies on immune markers specific to gynecological cancers.
o Analysis of clinical trial and real-world data on biomarker-driven immunotherapeutic approaches.
o Exploration of AI technologies in the discovery of multi-omics biomarkers.
Please note that Dr Anand Rotte is an employee of Arcellx Inc, a clinical stage biotech developing CAR-T cell therapies and I own stocks and stock options for Arcellx. Also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
This research aims to overcome existing challenges and seize the opportunity to advance the identification and validation of immune biomarkers capable of prognosticating and predicting responses to immunotherapies, especially beyond the well-recognized markers like PD-L1, TMB, and MSI. Recent innovations integrating high-dimensional data analysis and multi-omics have propelled forward our understanding of the immunological landscape. However, these methodologies require further refinement and clinical integration to enhance precision in immunotherapy strategies. This research encourages contributions that span basic research, translational applications, and clinical investigations, particularly studies utilizing paired tumor samples, liquid biopsies, and exploring the microbiome’s role in modulating immune responses.
To deal with the immune dynamics of cancer, this research topic calls for contributions encapsulating a range from basic research findings to advanced translational insights. Specific themes of interest include, but are not limited to:
o Novel immune predictive and prognostic biomarkers in oncology.
o Mechanisms of immune evasion and strategies to counteract resistance to immunotherapy.
o Research utilizing paired tumor samples or biomarkers from liquid biopsies to understand tumor-immune interplay.
o Examination of immune cell interactions within tumor environments in relation to immunotherapeutic efficacy.
o The influence of microbiome and metabolome analyses on immune responses and clinical outcomes.
o Application of multi-omics to investigate immune biomarkers in oncology.
o Focused studies on immune markers specific to gynecological cancers.
o Analysis of clinical trial and real-world data on biomarker-driven immunotherapeutic approaches.
o Exploration of AI technologies in the discovery of multi-omics biomarkers.
Please note that Dr Anand Rotte is an employee of Arcellx Inc, a clinical stage biotech developing CAR-T cell therapies and I own stocks and stock options for Arcellx. Also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Immuno-oncology, Novel immune biomarkers, Liquid biops, Tumor microenvironment, Gynaecological malignancies, Immune tumor evasion, Microbiota and immunotherapy, Translational research, Paired tumor samples, Multi-omics, biomarker immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
